Therapy News and Research

RSS

Gas transfer excels in predicting mortality in COPD

Researchers say that measuring gas transfer is the most effective way to predict mortality in chronic obstructive pulmonary disease, after finding that it outperformed both spirometry and plethysmography for the purpose.

3 Oct 2013

First Edition: October 3, 2013

Today's headlines include reports about how the federal and state health exchanges worked on their second day of operations. In the background, the congressional budget stand off continues.

3 Oct 2013

Genetic condition that attacks multiple organs can be detected using new MRI technique

A genetic condition that attacks multiple organs and usually results in fatal heart problems can be detected using a new MRI technique that was developed at the University of Alberta. The discovery of this new diagnostic tool has resulted in updated clinical guidelines for the diagnosis and treatment of Fabry disease in Canada.

3 Oct 2013

Cambridge Consultants helps MSF’s efforts to widen access to HIV viral load tests

Cambridge Consultants is working with Médecins Sans Frontières (MSF) to help support moves to expand access to vital diagnostic tests, which paves the way for better treatment of HIV in some of the world’s least-developed countries.

3 Oct 2013

Radiofrequency ablation leads to remission of dysplastic Barrett's esophagus

Radiofrequency ablation (RFA) leads to remission for 91 percent of patients with dysplastic Barrett's esophagus, according to new figures published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

3 Oct 2013

Research: Children with inherited anti-inflammatory defect may have predisposition to lymphoma

New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, the Journal of the American Society of Hematology (ASH), reveal an important association between the genetic defect, which causes chronic intestinal inflammation and early onset inflammatory bowel disease, and its role in cancer development in infants and children.

3 Oct 2013

UCLA study shows how cocaine makes immune cells susceptible to HIV

In many ways, the spread of HIV has been fueled by substance abuse. Shared needles and drug users' high-risk sexual behaviors are just some of the ways that narcotics such as cocaine have played a key role in the AIDS epidemic in much of the world.

3 Oct 2013

AtheroMed completes patient enrollment in EASE clinical study for treating PAD

AtheroMed, a developer of innovative technologies for treating peripheral artery disease, announced that it has completed patient enrollment in the EASE clinical study. The EASE study results will be presented by Dr. Stephen Williams, Director, Vascular Medicine Center at Johns Hopkins University, during a Late Breaking Clinical Trials Session on Wednesday, October 9th, at the Vascular Interventional Advances conference in Las Vegas.

2 Oct 2013

Klox Biophotonic System gets approval in Canada for treatment of acne vulgaris

KLOX Technologies Inc. announces the approval in Canada of the Klox Biophotonic System (also known as the Lumigel Cleanse System) for the treatment of acne vulgaris after receiving this week a Medical Device License from the Therapeutic Products Directorate - Medical Devices Bureau of Health Canada

2 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

Hypertension Drug May Aid Cancer Treatment

...

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

2 Oct 2013

Laboratory testing kit that estimates risk of breast cancer relapse gets FDA approval

A laboratory testing kit that estimates the risk of breast cancer relapse in spite of anti-hormone treatment has received approval from the U.S. Food and Drug Administration.

2 Oct 2013

Genetic discovery could take guesswork out of prescribing correct dose of drugs

The discovery of genetic differences affecting up to a third of the population could take the guesswork out of prescribing the correct dose of 25 percent of drugs currently on the market, researchers say.

2 Oct 2013

Nia exercise benefits individuals with breast cancer

Researchers from ProMedica Cancer Institute have released new findings about the benefits of Nia exercise for individuals with breast cancer. Nia is a sensory-based movement practice that heals the body using music and movement.

2 Oct 2013

Remote stroke service increases rate of tPA therapy at community hospitals

A telestroke service increases the rate of effective tissue plasminogen activator therapy for patients with acute ischemic stroke treated at community hospitals, according to a report in the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

2 Oct 2013

Multiple aspects to severe bipolar mixed states

Researchers have identified four subgroups of severe bipolar mixed states, characterized by distinct symptomatologic presentations.

1 Oct 2013

Ilesto ICD/CRT-D devices from BIOTRONIK approved by FDA

BIOTRONIK, a leading manufacturer of cardiovascular medical technology, announced it has received approval from the Food and Drug Administration (FDA) for its Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices). BIOTRONIK follows this milestone with the launch of its next generation unique technology platform Ilesto DX.

1 Oct 2013

Researchers compare cardiovascular safety of two commonly used oral estrogen medications

The oral hormone therapy conjugated equine estrogens, which is used by women to relieve menopause symptoms, appears to be associated with increased risk for venous thrombosis (VT, blood clots) and possibly myocardial infarction (heart attack), but not ischemic stroke risk, when compared with the hormone therapy oral estradiol, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

1 Oct 2013